C950T and C1181G osteoprotegerin gene polymorphisms in myeloma bone disease

References

• Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23:435–41.
   PubMed Web of Science ®Google Scholar
• Esteve FR, Roodman GD. Pathophysiology of myeloma bone disease. Best Pract Res Clin Haematol. 2007;20:613–24.
   PubMed Web of Science ®Google Scholar
• Mundy GR, Bertolini DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol. 1986;13:291–9.
   PubMed Web of Science ®Google Scholar
• Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am. 1997;11:27–42.
   PubMed Web of Science ®Google Scholar
• Wittrant Y, Théoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004;1704:49–57.
   PubMed Web of Science ®Google Scholar
• Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol. 2005;16:1223–31.
   PubMed Web of Science ®Google Scholar
• Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050–5.
   PubMed Web of Science ®Google Scholar
• Martini G, Gozzetti A, Gennari L, Avanzati A, Nuti R, Lauria F. The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma. Haematologica2006;91:1720–1.
   PubMed Web of Science ®Google Scholar
• Stejskal D, Bartek J, Pastorková R, Růzicka V, Oral I, Horalík D. Osteoprotegerin, RANK, RANKL. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2001;145:61–4.
   PubMedGoogle Scholar
• Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005;106:2472–83.
   PubMed Web of Science ®Google Scholar
• Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004;341:19–39.
   PubMed Web of Science ®Google Scholar
• Glass DA II, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8:751–64.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barillé S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527–33.
   PubMed Web of Science ®Google Scholar
• Sezer O, Heider U, Zavrski I, Kühne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094–8.
   PubMed Web of Science ®Google Scholar
• Jakob C, Goerke A, Terpos E, Sterz J, Heider U, Kühnhardt D, et al. Serum levels of total-RANKL in multiple myeloma. Clin Lymphoma Myeloma. 2009;9:430–5.
   PubMedGoogle Scholar
• Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet. 2002;11:2119–27.
   PubMed Web of Science ®Google Scholar
• Chong B, Hegde M, Fawkner M, Simonet S, Cassinelli H, Coker M, et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res. 2003;18:2095–104.
   PubMed Web of Science ®Google Scholar
• Middleton-Hardie C, Zhu Q, Cundy H, Lin JM, Callon K, Tong PC, et al. Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL. J Bone Miner Res. 2006;21:438–45.
   PubMed Web of Science ®Google Scholar
• Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260–8.
   PubMed Web of Science ®Google Scholar
• Beyens G, Daroszewska A, de Freitas F, Fransen E, Vanhoenacker F, Verbruggen L, et al. Identification of sex-specific associations between polymorphisms of the osteoprotegerin gene, TNFRSF11B, and Paget's disease of bone. J Bone Miner Res. 2007;22:1062–71.
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res. 2002;17:1245–55.
   PubMed Web of Science ®Google Scholar
• Arko B, Prezelj J, Komel R, Kocijancic A, Hudler P, Marc J. Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2002;87:4080–4.
   PubMed Web of Science ®Google Scholar
• Roshandel D, Holliday KL, Pye SR, Boonen S, Borghs H, Vanderschueren D, et al. Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men. J Bone Miner Res. 2010;25:1830–8.
   PubMed Web of Science ®Google Scholar
• Mencej-Bedrač S, Preželj J, Marc J. TNFRSF11B gene polymorphisms 1181G > C and 245T > G as well as haplotype CT influence bone mineral density in postmenopausal women. Maturitas 2011;69:263–7.
   PubMed Web of Science ®Google Scholar
• Goranova-Marinova V, Goranov S, Pavlov P, Tzvetkova T. Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clin Corr Haematol. 2007;92:1000–1.
   Google Scholar
• Morinaga T, Nakagawa N, Yasuda H, Tsuda E, Higashio K. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. Eur J Biochem. 1998;254:685–91.
   PubMedGoogle Scholar
• Choe WS, Kim HL, Han JK, Choi YE, Seo B, Cho HJ, et al. Association between OPG, RANK and RANKL gene polymorphisms and susceptibility to acute coronary syndrome in Korean population. J Genet. 2012;9:87–9
   Google Scholar